Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: semi_infinite who wrote (14671)	12/14/2004 2:24:56 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

group of patients that are relatively helpless when it comes to doing their own research The fact is it is very difficult indeed to compare these treatments across trials. Without access to detailed statistics it is virtually impossible. When you are dealing with different types of disease in different stages it becomes even harder. At some point even the most diligent patient throws up his or her hands and lets the doctor decide. And my earlier diatribe was simplistic as well. Some doctors like to try new stuff. Others like to stick with the "tried and true" and wait a few years to see how new drugs pan out. My guess is that if QLTI is weak on approval here then it's probably a decent buy. I have a little tucked away - but nothing major at all. Peter